CIRCIO HOLDING ASA Oslo, Norway ,11 August 2022 -Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2022 results on Thursday18 August 2022 .Targovax's management will present the results at a live streamed webcast at10:00 am CET to investors, analysts and the press. The results report and the presentation will be available at www.targovax.com (https://www.targovax.com/en/financial-reports/) in the Investors section from07:00 am CET , on18 August 2022 . Presentation There will be a virtual presentation of the results with a live webcast 18 August at10.00 am CET . You can join the webcast here (https://channel.royalcast.com/landingpage/hegnarmedia/20220818_10/). It will be possible to ask questions during the presentation. For further information, please contact:Erik Digman Wiklund , CEO Phone: +47 413 33 536 Email: erik.wiklund@targovax.comRenate Birkeli , Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires:Andreas Tinglum - Corporate Communications (Norway ) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no AboutTargovax Activating the patient's immune system to fight cancerTargovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors.Targovax's focus is to activate the patient's immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives.Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, multiple myeloma and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.Targovax's lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 will progress into a phase 2 trial in multiple combinations in melanoma patients resistant to PD1 checkpoint blockade. Building on successful studies demonstrating clinical efficacy and providing deep mechanistic insights, the ONCOS platform is being expanded into delivery of circular RNA (circRNA). In addition,Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, due to enter the clinic in the second half of 2022. This providesTargovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.
Click here for more information
© Oslo Bors ASA, source
